BioCurate expands Board and Investment Committee to support next phase of growth
Author
Date
BioCurate
June 25, 2021
BioCurate, an independently operated joint venture between the University of Melbourne and Monash University, and with support of the Victorian State Government, today announced the appointment of Dr Marie Lindner as an Independent Director on the BioCurate Board and member of the Investment Committee, and of Josephine Wu as an independent member of BioCurate’s Investment Committee.
BioCurate is excited to have these two highly-skilled women with extensive international experience join the Company and provide guidance to our mission to translate new discoveries into novel therapies and take these to the global market.
Dr Marie Lindner has worked in executive roles in pharmaceutical, biotech, venture capital, start-up and medtech companies with experience across therapeutic areas and modalities for over 30 years. This has included working in business and clinical development at several medium-large biotech and pharma companies, such as Novartis Pharmaceuticals, co-founding two startups, being a partner at a startup biotech VC group, and playing a senior role in a cell therapy company.
Marie also has experience as a practising clinician, having been a board-certified doctor specialising in internal medicine and clinical nutrition at the Hospital of the University of Pennsylvania and the Children’s Hospital of Philadelphia. Now retired, Marie maintains several consultancies and is active on a number of boards.
“I am delighted to bring my global experience to support this innovative Melbourne venture succeed in the development of novel therapeutics, and to highlight to the world the exciting combination of pairing high quality medical research with the capability of BioCurate’s world class team,” said Marie.
Josephine Wu has over 19 years of hedge fund, family office and global asset management experience including over 10 years of listed, pre-IPO and early-stage Pan-Asia healthcare investment experience. She is the founder and current CIO of Aionious Capital Limited, a dedicated healthcare investment company which invests and provides business development and commercialisation strategies in the pan-Asia region, specifically in China.
Josephine brings an extensive network of experts in operational, clinical, market positioning and regulatory knowledge in the Pan-Asia healthcare landscape. Her investments in healthcare companies at different stages have led to the successful commercialisation launches of pharmaceutical products, regulatory approvals, and the signing of strategic partnerships in commercialisation transactions and IPOs.
“Australian universities are renowned for their high-quality research. With that, I am excited to apply my specialised global investment experience and knowledge to help commercialise this research into products that will be available to patients around the world,” said Josephine.
We welcome Marie and Josephine to BioCurate and look forward to working with them as the Company embarks on its next phase of growth.
Click here to read more about Marie.
Click here to read more about Josephine.
About BioCurate
BioCurate is a bold, collaborative venture, dedicated to delivering benefits to the community by helping to advance Australian research and innovation globally. Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate identifies promising biomedical research discoveries and manages their translation into high quality pre-clinical candidates with the aim to develop potential novel human therapeutics.
We operate in the under-resourced, yet critical, early phases of therapeutic development to overcome common barriers to success and drive early decisions. BioCurate is operationally independent, with a team of experts that brings decades of scientific and commercial expertise, enabling us to recognise and realise real-world potential and providing a critical bridge between academia and industry. Governance is provided by an experienced Board with an independent Board Chair, the Hon John Brumby AO, supported by Directors with specialist backgrounds in biotechnology, investment and corporate governance.
For more information about BioCurate, visit www.biocurate.com
Media contact
Linda Peterson, COO and Company Secretary
E: l.peterson@biocurate.com
